Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00699777 · ClinicalTrials.gov registry record · Phase 1
Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects
A Phase 1 study of Osteoporosis, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 4
- Study locations
NCT00699777: Completed Phase 1 study of Osteoporosis, sponsored by Warner Chilcott.
NCT00699777 is a Phase 1 study of Osteoporosis that has completed, run by Warner Chilcott. The registered enrollment target is 96 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00699777, a Phase 1 study of Osteoporosis, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is a randomized, open-label, crossover study to assess the bioequivalence of 1 risedronate 150 mg tablet versus 2 risedronate 75 mg tablets administered as a single oral dose. Approximately 320 subjects will be enrolled from 4 study centers in the U.S.
Conditions Studied
Interventions
- DRUG Risedronate
Study Locations (4)
Florida
- Research Site - Gainesville
- Research Facility - Miramar
Texas
- Research Facility - Austin
- Research Facility - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
What the finished NCT00699777 record still lists
NCT00699777 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Osteoporosis appearing as the primary indexed condition, and to 1 intervention - of which Risedronate is the first listed.
NCT00699777 reports a single indexed study location in Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT00699777 about?
NCT00699777 is a clinical study titled "Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects". This study is a randomized, open-label, crossover study to assess the bioequivalence of 1 risedronate 150 mg tablet versus 2 risedronate 75 mg tablets administered as a single oral dose. Approximately 320 subjects will be enrolled from 4 study centers in the U.S.
What is the current status of trial NCT00699777?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2008-01. Estimated completion is 2008-04.
What conditions does trial NCT00699777 study?
This clinical trial studies the following conditions: Osteoporosis.
What interventions are being tested in trial NCT00699777?
The interventions under investigation include: Risedronate (DRUG).
Who is sponsoring clinical trial NCT00699777?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00699777 being conducted?
This trial has 4 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00699777's enrollment target sits among peer trials
96 40th of 84 higher than 45 of 84 other Osteoporosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis
ACTIVE NOT RECRUITING · Phase 1
-
Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose
COMPLETED · Phase 1
-
Patient- and Physician-Based Osteoporosis Education
COMPLETED · Phase 1
-
Improving Bone Health in Adolescent Girls: The Youth Osteoporosis and Understanding Total Health (YOUTH) Study
COMPLETED · Phase 1
-
A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women
COMPLETED · Phase 1
-
A Comparison Study of PF708 and Forteo in Healthy Subjects
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia